Acquisitions by Spain's Ferrer and Rubio
The Spanish pharmaceutical group Ferrer has acquired Gelos, a company with forecast annual sales for 2007 of 26.0 million euros ($37.5 million). The enterprise makes Gelocatil (codeine and paracetamol), the second best-selling over-the-counter analgesic in Spain, and has a production unit with an annual capacity of 600 million units. Financial terms were not disclosed.
An acquisition has also been completed by Rubio, with the purchase of Portugal's Pharmout, which markets and distributes drug products - both its own and licensed-in drugs. Sales last year reached 6.0 million euros. Rubio specializes in drugs for the treatment of low-incidence diseases including hyperactivity and attention deficit.
Grifols' investment plans
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze